# Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

> **NCT06221683** · PHASE2 · RECRUITING · sponsor: **Children's Hospital of Soochow University** · enrollment: 500 (estimated)

## Conditions studied

- AML, Childhood
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Homoharringtonine
- **DRUG:** Cytarabine
- **DRUG:** Etoposide
- **DRUG:** Venetoclax
- **DRUG:** Mitoxantrone hydrochloride liposome
- **DRUG:** Recombinant Human Granulocyte Colony-Stimulating Factor
- **DRUG:** Idarubicin Hydrochloride
- **DRUG:** Sorafenib
- **DRUG:** Gilteritinib
- **DRUG:** Avapritinib

## Key facts

- **NCT ID:** NCT06221683
- **Lead sponsor:** Children's Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06221683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06221683, "Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06221683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*